17.71
3.95 (28.71%)
AISkor Stockmoo
| Nilai 30% | -3.9 |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Penilaian Relatif info | NA |
| Pertumbuhan Tersirat info | NA |
| Sejarah Penilaian info | NA |
| Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info | |
| Pulangan di bawah kos modalnya. Pulangan atas modal menurun. info | |
| Masa 30% | -2.2 |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Aliran menaik sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info | |
| Corak Lilin info | NA |
| Aliran bagi Tempoh Pegangan Anda info | NA |
| Sentimen 20% | 0.0 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Sentimen Berita info | NA |
| Wang Pintar 20% | 0.2 |
| Aktiviti Orang Dalam info | NA |
| Institusi bersih +0.15% daripada saham dalam pemfailan 13F terkini: 35 pemegang menambah, 18 mengurang (suku berakhir 30 Sep 2026). info | |
| Kedudukan jual singkat -5.0% dari 31 Aug hingga 30 Oct 2026, 12.5 hari untuk tutup (FINRA). info | |
| Keadaan pasaran dan sektor lemah. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor ketinggalan berbanding pasaran. | |
| Tonggak-tonggak sependapat, jadi skor diperkukuh. | |
| Tidak dikira dalam skor | |
| Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info | |
| Aliran jangka pendek naik, jangka sederhana dan panjang turun. Momentum jangka pendek menurun. info | |
| Harga di antara sokongan dan rintangan. Paras sokongan dan rintangan menaik. info | |
| Skor Akhir | -2.42 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Greenwich LifeSciences, Inc. | Bercampur | Menaik |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| GLSI | - | - | - | 70.35 |
| GLTO | 2 B | - | - | - |
| IPA | 96 M | - | - | 5.98 |
| ACIU | - | - | - | 6.56 |
| DNLI | - | - | - | 3.24 |
| GHRS | - | - | - | 3.65 |
|
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual’s immune system to selectively attack cancer cells to inhibit the spread of cancer. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 52.30% |
| % Dimiliki oleh Institusi | 9.47% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Institusi
Pemilikan institusi: 13.79%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 35 | 189,628 |
| Berkurang | 18 | 137,114 |
| Baharu | 4 | 18,060 |
| Dijual habis | 7 | 48,039 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
Kedudukan Jual Singkat
| Penyelesaian | Saham | Hari untuk tutup |
|---|---|---|
| 30 Oct 2026 | 1,578,166 | 12.5 |
| 15 Oct 2026 | 1,552,366 | 10.7 |
| 30 Sep 2026 | 1,580,950 | 11.4 |
| 15 Sep 2026 | 1,631,150 | 19.8 |
| 31 Aug 2026 | 1,660,969 | 11.4 |
| 14 Aug 2026 | 1,593,720 | 13.3 |
Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 17 Nov 2026 | Yahoo Finance |
Greenwich LifeSciences Gears Up For Two Breast Cancer Vaccine Presentations — Retail Says ‘Peptide Vaccine Works’ After SLS Trial Success
Greenwich said two research abstracts related to its experimental breast cancer drug were accepted for the San Antonio Breast Cancer Symposium, scheduled for December 8 to 11… |
| 17 Nov 2026 | Yahoo Finance |
Greenwich LifeSciences Announces Acceptance of Abstracts at SABCS 2026
STAFFORD, Texas, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast… |
| 15 Sep 2026 | Yahoo Finance |
3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets
Rising rates raise the bar for risky science. Meet three clinical-stage cancer stocks with pristine, debt-free balance sheets, plus the screener that surfaces the rest. |
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |